A Life-Threatening Condition and Unmet Medical Need
Esophageal Atresia (EA) is a devastating congenital defect that causes infants to be born with a gap between their esophagus and stomach.
Worldwide, EA occurs in approximately 1 in 2,500-3,500 live births
Although the disorder is most often detected right after birth when the baby is unable to feed properly, it is sometimes possible to detect the condition by ultrasound as evidenced by an abundance of amniotic fluid.
Currently there are no disease dedicated treatments for EA. Current protocol is surgery to close the gap. This can be done in some cases by reattaching the two ends together. In many cases the only option is to anatomically replace the missing esophagus either by pulling up the stomach or by using a section of the gastrointestinal tract. Any of these surgical techniques of esophageal replacement are plagued by complications, like anastomotic leaks and scaring strictures that require further treatments.
Biostage is developing a Cellspan Implant that can be used as an esophageal substitute. This replacement implant is combined with a baby’s own stem cells aims to avoid the use of the baby’s stomach or intestine with the goal of improving short- and long-term outcomes.
Learn more about this life-threatening congenital abnormality.
Designed to bridge the gap between two portions of the esophagus.
A large unmet medical need for patients and their families.
Preclinical studies demonstrate consistent regeneration is feasible.
At the forefront of tissue engineering and regenerative medicine.